APUS
Apimeds Pharmaceuticals US, Inc.
Next earnings ≈ Aug 25, 2026 · est. from filing cadence
$0.96▼ -42.53%
over 1Y
L $0.86EODHDH $38.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W+1.6%
1M-32.4%
3M-49.7%
YTD-94.2%
1Y-42.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.07x).
Return on equity -3.9% · latest
Apimeds Pharmaceuticals US, Inc. shows limited reported revenue, and -3.9% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$747K | -$1.28M | -$11.9M |
| Net income | -$778K | -$1.39M | -$6.00M |
| Diluted EPS | -$0.17 | -$0.18 | -$0.55 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)-6.1%
Free cash flow-$8.98M
Total debt$20.0K
Net cash$1.62M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+53.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-15). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-26open ↗NT 10-QPeriod ending 2026-03-312026-05-15open ↗SCHEDULE 13D/AFiling2026-05-07open ↗8-KPeriod ending 2026-05-052026-05-05open ↗10-KPeriod ending 2025-12-312026-05-04open ↗8-KPeriod ending 2026-04-242026-05-04open ↗8-KPeriod ending 2026-04-172026-04-22open ↗8-KPeriod ending 2026-04-152026-04-16open ↗425Filing2026-04-09open ↗8-K/APeriod ending 2026-03-202026-04-09open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗SCHEDULE 13D/AFiling2026-03-30open ↗
Frequently asked
- Is Apimeds Pharmaceuticals US, Inc. (APUS) a buy?
- APUS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.07x).
- What is Apimeds Pharmaceuticals US, Inc.'s quality score?
- APUS scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001894525, latest 10-Q filed 2026-05-26) · as of 6/22/2026, 11:30:10 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.